Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Pulmonary Hypertension
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Charcot-Marie-Tooth Disease, Multiple Sclerosis
Interventions: Electrical impedance myography (EIM); Device
Lead sponsor: Skulpt, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: Phoenix, Arizona • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Fabry Disease
Interventions: Pegunigalsidase-alfa; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Birth, Spontaneous Abortion
Interventions: acetylsalicylic-acid (aspirin), Folic acid; Drug · Dietary Supplement
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 1,228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 4
States / cities: Denver, Colorado • Buffalo, New York • Scranton, Pennsylvania + 1 more

Conditions: X-Linked Retinitis Pigmentosa
Interventions: rAAV2tYF-GRK1-RPGR; Biological
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 8 Years to 50 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more

Conditions: Pediatric Surgical Procedures, Adult Surgical Procedures, Adult Gynecological Procedures, Adult Urological Procedures, Adult Thoracic Procedures
Interventions: HARMONIC 700 Shears; Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: Up to 110 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Indianapolis, Indiana • New York, New York

Conditions: Healthy Volunteer, Urea Cycle Disorder
Interventions: Placebo, SYNB1020; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Bacterial Infection
Interventions: Meropenem, Standard antibiotic therapy; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 10
States / cities: Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more

Conditions: Head and Neck Cancer
Interventions: gene therapy, interleukin-2 gene, methotrexate; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Tumor
Interventions: DOSI; Device
Lead sponsor: Beckman Laser Institute and Medical Center; Other
Eligibility: 21 Years to 80 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Costa Mesa, California • Irvine, California • San Francisco, California

Conditions: Nasal Airway Obstruction
Interventions: Not listed
Lead sponsor: Aerin Medical; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 27 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glulisine, Insulin Glargine, Premixed Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Exudative Age-related Macular Degeneration
Interventions: RBM-007 Injectable Solution, Aflibercept, Sham; Drug
Lead sponsor: Ribomic USA Inc; Industry
Eligibility: 55 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 5 more

Conditions: Urinary Tract Infections, Pyelonephritis Acute, Intraabdominal Infections
Interventions: Sulopenem; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 12 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lower Back Pain
Interventions: Institutional interventions, PCPs interventions, Patient interventions; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 20
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 14 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Concord, California + 43 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Adipose Derived Stem Cell (ADSC) Therapy; Drug
Lead sponsor: Kimera Society Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Davie, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more

Conditions: Rheumatoid Arthritis
Interventions: LX3305 low dose, LX3305 mid dose, LX3305 high dose, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 13
States / cities: Gainesville, Florida • Orange Park, Florida • Orlando, Florida + 10 more

Conditions: Breast Reconstruction
Interventions: FlexHD ADM (Cohort A), AlloDerm RTU ADM (Cohort B); Biological
Lead sponsor: Musculoskeletal Transplant Foundation; Other
Eligibility: 18 Years and older · Female only
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Chicago, Illinois • Evanston, Illinois • New Orleans, Louisiana + 4 more

Conditions: Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria, Dietary Hyperoxaluria
Interventions: ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Los Angeles, California • Daytona Beach, Florida • Jacksonville, Florida + 13 more

Conditions: Bacterial Vaginosis
Interventions: SYM-1219; Drug
Lead sponsor: Symbiomix Therapeutics; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 34 more

Conditions: Femoral Neck Fractures
Interventions: Sliding Hip Screw, Cancellous Screws, Vitamin D, Vitamin D Placebo; Procedure · Drug
Lead sponsor: McMaster University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 10
States / cities: Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 7 more

Conditions: Renal Cell Carcinoma
Interventions: Bevacizumab, Ixabepilone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Bethesda, Maryland • Charleston, South Carolina

Search by objective public record fields.

Targeting Right Ventricle in Pulmonary Hypertension Gilead

Study of Electrical Impedance Myography (EIM) in ALS

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

The Effects of Aspirin in Gestation and Reproduction

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

A Study of HARMONIC 700 Shears With Advanced Hemostasis in Pediatric and Adult Surgical Procedures

Safety and Tolerability of SYNB1020-CP-001

Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI

A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.

Insulin Glargine "All to Target" Trial

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents

Improving Access to Chiropractic Care in Community Health Centers

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2)

Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer